UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-42004

NEWGENIVF GROUP LIMITED
(Exact name of registrant as specified in its charter)

36/39-36/40, 13th Floor, PS Tower
Sukhumvit 21 Road (Asoke)
Khlong Toei Nuea Sub-district
Watthana District, Bangkok 10110
Thailand
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 16, 2026

NEWGENIVF GROUP LIMITED

By: /s/ Wing Fung Alfred Siu
Name: Wing Fung Alfred Siu
Title: Chairman of the Board and Director

Exhibit 99.1

NewGen Provides Business Update

BANGKOK, November 16, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today provided an update on its businesses.

Nodexus and NX One

In July 2025, the Company acquired advanced cytometry intellectual property and equipment. The Company has engaged Shenzhen Siyu Enterprise Management Consulting Co., Ltd. as its regulatory consultant for registration of its NX One microfluidic platform with China's National Medical Products Administration ("NMPA").

Nodexus Limited, a wholly owned Hong Kong subsidiary of the Company, has also signed a non-binding collaboration agreement with Hainan Provincial Cancer Hospital. The agreement records the parties' intent to collaborate on scientific validation, clinical research and eventual clinical translation of the NX One device in tumor precision diagnosis and treatment and in cell research. The parties intend the collaboration to generate real-world data that may support future clinical validation and clinical application of NX One in China. The agreement is non-binding, and there can be no assurance that a definitive agreement will be entered into.

K25.ai

The Company has completed the acquisition of 2% of the equity interest in PredicXion Group Limited, which operates K25.ai. The Company has also agreed to acquire a further 11% of equity interests. On November 10, 2026, K25 Group announced that it plans to launch K25.fun this month. K25.fun is a new membership platform bringing exclusive concert experiences, limited-edition collectibles, and fan quests to K-pop audiences across Asia-Pacific. This launch demonstrates K25's ability to turn audience engagement into new consumer revenue verticals.

Ras Al Khaimah Real Estate Project

The Company has paid deposits of US$4.71 million toward the acquisition of land for its real estate development project in Ras Al Khaimah, United Arab Emirates. A definitive sale and purchase agreement for the land has not yet been executed.

IVF Business

Revenue from the Company's IVF and assisted reproductive treatment business was broadly flat for the six months ended June 30, 2026 compared with the same period in 2025. Management attributes this to lower demand for fertility services across the industry and the effect of the Thailand–Cambodia conflict on patient travel.

Selected Balance Sheet Data (unaudited)

As of June 30, 2026, as reflected in the Company's unaudited condensed consolidated financial statements for the six months then ended furnished on Form 6-K/A on October 27, 2026:

Cash and cash equivalents were approximately US$1.02 million.

Total assets were approximately US$36.4 million, including deposits for land acquisition of US$4.71 million.

Equity attributable to shareholders of the Company was approximately US$26.4 million.

Total shareholders' equity, including non-controlling interests, was approximately US$25.7 million.

The increase in total assets compared with June 30, 2025 primarily reflects the acquisition of the cytometry intellectual property in July 2025 and the Company's investment in K25.ai.

About NewGen

NewGenIVF Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF's legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company's website is not incorporated by reference into this press release.

About Shenzhen Siyu Enterprise Management Consulting Co., Ltd.

Shenzhen Siyu (www.siyu-com.com) is a regulatory consulting firm experienced in China medical device registration. It is serving as full-process regulatory consultant to NewGen for the NX One NMPA registration program, including classification strategy, type-testing coordination, dossier preparation, and regulatory communications.

About Nodexus Limited

Nodexus Limited is a Hong Kong-incorporated company and the developer of the NX One microfluidic platform. It is a subsidiary within the NewGen group focused on advancing the commercialization of NX One for precision oncology applications.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's plans to seek registration of NX One with the NMPA and the U.S. Food and Drug Administration; the potential listing of Nodexus Limited under Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; the proposed collaboration with Hainan Provincial Cancer Hospital; the completion of the Company's investment in K25.ai, including payment of the remaining cash consideration; the planned launch of K25.fun; the completion of the land acquisition for the Company's real estate development project in Ras Al Khaimah; and trends in the Company's IVF and assisted reproductive treatment business.

These forward-looking statements are based on the Company's current expectations, estimates, projections and assumptions as of the date of this press release and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks and uncertainties include, among others: the risk that required regulatory registrations for NX One are not obtained or are subject to material delay; the risk that the collaboration with Hainan Provincial Cancer Hospital does not proceed or does not generate supportive data; the risk that the potential listing of Nodexus Limited does not occur, and that any such listing dilutes the Company's interest in Nodexus Limited; the possibility that the K25.ai transaction is not completed on the terms described or at all, including the Company's ability to fund its remaining payment obligations; the risk that the carrying value of the Company's investment in K25.ai is not realized and may be impaired; risks generally associated with strategic investments, including the Company's limited control over K25.ai's business; regulatory risk specific to prediction-market and information-market products; the risk that no definitive agreement for the Ras Al Khaimah land is concluded or that the Company's deposits are not recovered; geopolitical risks, including conflict in the Middle East and between Thailand and Cambodia; changes in demand for fertility services; liquidity and capital requirements risk; and business transformation and execution risk arising from the Company's ongoing strategic pivot across multiple new business lines. Additional risks are described in the Company's Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.

All information provided in this press release is as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.

Contacts

ICR, LLC

Robin Yang

Phone: +1 (212) 537-3847

Email: Newgenivf.IR@icrinc.com